Aa
Aa
A
A
A
Close
Avatar universal

increasing ribba (copegus)

in my 14 week of therapy genetype G1 a and still dectable
no apparant  side effects as of first day of therapy.
Began with extremely high virus level
Doc suggested after week 6 to go upto 1600 copegus
decided first not to follow orders as to many worries concerning increasing pills.
Just tried 1400 for 10 days and no side effects.
Gone up as of this Sunday morning to 1600 copegus (ribba)
Would like to hear from others following such treatment or know of anyone doing such a therapy and does it really help?
4 Responses
Sort by: Helpful Oldest Newest
Avatar universal
thans for your concern... I am however acute Hep c and in the first 6 months of accute still and unfortunately the start viral load was extremely high.
My doc told me from the outset that I would not have a non dectale until well after 12 week and expected by 12 week around 5000 ml so he was not far off.
I am als HIV 25 years so have two lood born viruses to contend with.
Will continue on 1400 copegus right through therapy and will post again with my results in 4 weeks and cross my fingers then that it is non dectable.
I did start on 800 copegus per day  for 10 days  at the beginning which was too low for my weight 175 pounds as needed to see how it would effect me in terms of HIV
Helpful - 0
179856 tn?1333547362
at week 8           14.6

You hemo is very high for this late in treatment and for some reason it appears that you are not getting enough riba into your system to me.  Especially if you increased dosage. Are you taking it with fatty foods so that it has something to bind to and not be just washed out?  

You need to discuss this further with your doctor and let him know you did not comply with upping the meds at first so he can try something more aggressive at this point. Your VL is very high for this late and you only have ten weeks left to get rid of it completely.

Helpful - 0
Avatar universal
acute HEP C  group G1 a
viral loadat start                    59 200 000  IU/ ml.
at week  4                              3 460 000  IU/ ml
at week 8                                  397 000  IU/ ml
at week 12                                    6 480  IU/ ml

Hb at  start was  17
at week 4           13 6    
at week 8           14.6
After 8 weeks  HB 14 and after after 8 weeks of theraphy
Combination Therapy week one copegus 1200  (3/3) and interferon up until 11 week
1from 11th week  1400 copegus (3/4) and interferon 180
Helpful - 0
Avatar universal
HCA
You asked virtually the same question very recently and received several replies.
What is your latest viral load?
Increasing ribavirin will not eliminate virus-it is your response to interferon which is critical as previously explained.
You need to be undetectable at week 24 in order to continue treatment.
Changing interferon is more likely to help at this time.
Helpful - 0
Have an Answer?

You are reading content posted in the Hepatitis C Community

Top Hepatitis Answerers
317787 tn?1473358451
DC
683231 tn?1467323017
Auburn, WA
Learn About Top Answerers
Didn't find the answer you were looking for?
Ask a question
Answer a few simple questions about your Hep C treatment journey.

Those who qualify may receive up to $100 for their time.
Explore More In Our Hep C Learning Center
image description
Learn about this treatable virus.
image description
Getting tested for this viral infection.
image description
3 key steps to getting on treatment.
image description
4 steps to getting on therapy.
image description
What you need to know about Hep C drugs.
image description
How the drugs might affect you.
image description
These tips may up your chances of a cure.
Popular Resources
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.